Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. 

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Hematology 28-May-21 21-Jun-21 23-July-21
Immunology – (ozanimod) Multiple Sclerosis 26-Mar-21 3-May-21 21-May-21
Immunology – (ozanimod) Ulcerative colitis 31-May-21 31-May-21 23-Jul-21
Oncology 1-Mar-21 29-Mar-21 23-Apr-21
Immunology – TYK2 (deucravacitinib) 8-Mar-21 12-Apr-21 14-May-21
Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy 10-May-21 14-Jun-21 9-Jul-21

 


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application